PharmaDepth

Asset

PEMBROLIZUMAB

Merck & Company Inc. Common Stock (new)

Revenue

PeriodRevenue
Q2 2026$8.4B
Q1 2026$8.0B
Q4 2025$8.3B
Q3 2025$8.1B
Q2 2025$8.0B
Q1 2025$7.2B
Q4 2024$7.8B
Q3 2024$7.4B
Q2 2024$7.3B
Q1 2024$6.9B
Q4 2023$6.6B
Q3 2023$6.3B
Q2 2023$6.3B
Q1 2023$5.8B
Q4 2022$5.5B
Q3 2022$5.4B
Q2 2022$5.3B
Q1 2022$4.8B
Q4 2021$4.6B
Q3 2021$4.5B
Q2 2021$4.2B
Q1 2021$3.9B
Q4 2020$4.0B
Q3 2020$3.7B
Q2 2020$3.4B
Q1 2020$3.3B
Q4 2019$3.1B
Q3 2019$3.1B
Q2 2019$2.6B
Q1 2019$2.3B
Q4 2018$2.2B
Q3 2018$1.9B
Q2 2018$1.7B

Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.

Clinical trials (253)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT06829199phase2withdrawn2025-03-262029-01-18Merck Sharp & Dohme LLCA Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)
NCT05933577phase3active_not_recruiting2023-07-192029-10-26Merck Sharp & Dohme LLCA Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT06305767phase1_2active_not_recruiting2024-03-282027-04-23Merck Sharp & Dohme LLCA Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06961006phase2recruiting2025-05-292028-07-22Merck Sharp & Dohme LLCA Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
NCT06428409phase1_2recruiting2024-06-202029-10-16Merck Sharp & Dohme LLCA Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)

FDA applications (2)

ApplicationTypeApplicant
BLA 125514BLAMSD International Business GmbH
BLA 761467BLAMerck Sharp & Dohme LLC

Marketed products (4)

  • KEYTRUDA
  • KEYTRUDA QLEX
  • KEYTRUDA QLEX
  • Keytruda